Floatz logo

SAR-BISPSMA, CU-64

Metastasis From Malignant Tumor of Prostate (Disorder)

Curium US LLCSmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
95/ 100

Competitive context

251 Active assets in the Metastasis From Malignant Tumor of Prostate (Disorder) cohort.

Asset / SponsorPhaseRating
PREDNISONE TABLETS
Mayo Clinic
Phase 4BBB
Fluciclovine
VA Greater Los Angeles Healthcare System
Phase 4BBB
LEUPROLIDE
Mayo Clinic
Phase 4BBB
Abiraterone Acetate
Mayo Clinic
Phase 4BB
PREDNISONE TABLETS
Mayo Clinic
Phase 4BB

View all 50 →

Same molecule, other indications

SAR-BISPSMA, CU-64 is also rated in:

CryotherapyDormant
B
Indicative ·
60 / 100
View asset →
prostate neoplasmDormant
B
Indicative ·
59 / 100
View asset →
prostate cancerDormant
B
Indicative ·
58 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →